Benjamin F. Edwards & Company, Inc. Xeris Biopharma Holdings, Inc. Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 3,000 shares of XERS stock, worth $10,530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,000
Previous 3,000
-0.0%
Holding current value
$10,530
Previous $7,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding XERS
# of Institutions
142Shares Held
59.9MCall Options Held
148KPut Options Held
45.7K-
Black Rock Inc. New York, NY10.3MShares$36.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$27.3 Million0.0% of portfolio
-
Caxton Corp Princeton, NJ5.11MShares$17.9 Million62.59% of portfolio
-
Center Book Partners LP Greenwich, CT3.48MShares$12.2 Million0.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.33MShares$11.7 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $477M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...